Roivant Sciences Ltd (ROIV) Stock Price, Quote & News

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythemat...

Industry: Biotechnology

Sector: Healthcare

Website: roivant.com

Address:

11-12 St. James's Square, Suite 1 3rd Floor, London, United Kingdom

DocPharm Oct. 3 at 9:22 PM

$ROIV wonder if they are taking Genevant public Weird for a prospectus for 2022 to be lumped in $ABUS

3 · Reply

GOLDENSAFEBETS Oct. 3 at 9:05 PM

$ROIV been here since 10.88 so many people sleeping on this play

0 · Reply

GOLDENSAFEBETS Oct. 3 at 9:04 PM

$ROIV

0 · Reply

AStrokeOfLuck Oct. 3 at 8:46 PM

$ROIV

0 · Reply

DocPharm Oct. 3 at 8:40 PM

$ROIV what’s the play here mgmt, after a buyback 🤔

0 · Reply

SpaceCityKid Oct. 3 at 2:49 PM

$ROIV Holding up near 52 week high is a good sign

0 · Reply

SweepCastApp Oct. 3 at 10:37 AM

$ROIV: Unusual Options Activity Alerted CALL flow observed 1500x contracts at Strike price of $16 Exp on 01/16/2026 with Premium of $203K and showing BULLISH Sentiment

0 · Reply

Dogstocks12 Oct. 1 at 7:49 PM

$ROIV Another 330k, calls at the ask

0 · Reply

Dogstocks12 Oct. 1 at 4:38 PM

$ROIV Big money options is in at and near ask

0 · Reply

biggestponzi Oct. 1 at 4:34 PM

$ROIV They have gone from 8 billion to 6 billion in 2 years

0 · Reply

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 24, 2025, 10:57 PM EDT - 10 days ago

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 5:45 AM EDT - 11 days ago

Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript

Sep 17, 2025, 3:43 PM EDT - 17 days ago

Roivant Sciences Ltd. - Special Call

Sep 17, 2025, 12:13 PM EDT - 17 days ago

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial

Sep 17, 2025, 8:21 AM EDT - 17 days ago

Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial

Sep 17, 2025, 7:00 AM EDT - 17 days ago

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Sep 11, 2025, 4:30 PM EDT - 23 days ago

Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Sep 8, 2025, 8:25 PM EDT - 26 days ago

Roivant Sciences Ltd. (ROIV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 7:00 AM EDT - 4 weeks ago

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Sep 3, 2025, 11:07 PM EDT - 4 weeks ago

Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript

Sep 3, 2025, 1:01 PM EDT - 4 weeks ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Aug 15, 2025, 9:30 AM EDT - 7 weeks ago

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack

Aug 11, 2025, 12:28 PM EDT - 7 weeks ago

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

Aug 11, 2025, 7:00 AM EDT - 7 weeks ago

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Jul 28, 2025, 4:05 PM EDT - 2 months ago

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Jun 16, 2025, 7:00 AM EDT - 3 months ago

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Jun 9, 2025, 4:05 PM EDT - 4 months ago

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

May 29, 2025, 2:17 PM EDT - 4 months ago

Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript

May 29, 2025, 7:00 AM EDT - 4 months ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 15, 2025, 4:10 PM EDT - 5 months ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

Apr 23, 2025, 12:13 PM EDT - 5 months ago

Roivant Sciences: Primed For Growth With A De-Risked Pipeline

Apr 21, 2025, 7:00 AM EDT - 5 months ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Mar 19, 2025, 7:45 AM EDT - 7 months ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 18, 2025, 4:32 PM EDT - 7 months ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Mar 3, 2025, 9:15 AM EST - 7 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS

Feb 10, 2025, 12:32 PM EST - 8 months ago

Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript

Feb 10, 2025, 7:00 AM EST - 8 months ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Feb 5, 2025, 12:12 PM EST - 8 months ago

Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)

Feb 3, 2025, 7:00 AM EST - 8 months ago

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Jan 29, 2025, 4:05 PM EST - 8 months ago

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Jan 13, 2025, 9:00 AM EST - 9 months ago

Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development

Dec 4, 2024, 8:30 AM EST - 10 months ago

Roivant Sciences: A Biotech Growth Play With Major Ambitions

Dec 3, 2024, 7:19 AM EST - 10 months ago

Roivant's lung disease drug fails mid-stage trial

Nov 12, 2024, 2:41 PM EST - 11 months ago

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Oct 29, 2024, 4:35 PM EDT - 1 year ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Oct 22, 2024, 12:31 PM EDT - 1 year ago

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Sep 18, 2024, 3:20 PM EDT - 1 year ago

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

OGN

Sep 18, 2024, 10:59 AM EDT - 1 year ago

Roivant Flips a Skin Drug to Organon

OGN

Sep 18, 2024, 7:30 AM EDT - 1 year ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

OGN

Sep 10, 2024, 6:30 AM EDT - 1 year ago

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

Sep 10, 2024, 6:30 AM EDT - 1 year ago

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Sep 9, 2024, 12:54 PM EDT - 1 year ago

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Roivant Provides Update on Graves' Disease Development Program

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Top Stocks Near Their 200-Day SMA

CCL CUK SM

Aug 22, 2024, 1:00 AM EDT - 1 year ago

Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses

Jun 7, 2024, 6:26 PM EDT - 1 year ago

The 'Undercovered' Dozen From June 1-6

ALNY CLOV CRSP ENVX GAM HAL LPA

Jun 2, 2024, 7:27 AM EDT - 1 year ago

Roivant Sciences: Executing On Huge Buyback Program With More To Come

May 30, 2024, 12:23 PM EDT - 1 year ago

Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript

May 30, 2024, 7:00 AM EDT - 1 year ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

DocPharm Oct. 3 at 9:22 PM

$ROIV wonder if they are taking Genevant public Weird for a prospectus for 2022 to be lumped in $ABUS

3 · Reply

GOLDENSAFEBETS Oct. 3 at 9:05 PM

$ROIV been here since 10.88 so many people sleeping on this play

0 · Reply

GOLDENSAFEBETS Oct. 3 at 9:04 PM

$ROIV

0 · Reply

AStrokeOfLuck Oct. 3 at 8:46 PM

$ROIV

0 · Reply

DocPharm Oct. 3 at 8:40 PM

$ROIV what’s the play here mgmt, after a buyback 🤔

0 · Reply

SpaceCityKid Oct. 3 at 2:49 PM

$ROIV Holding up near 52 week high is a good sign

0 · Reply

SweepCastApp Oct. 3 at 10:37 AM

$ROIV: Unusual Options Activity Alerted CALL flow observed 1500x contracts at Strike price of $16 Exp on 01/16/2026 with Premium of $203K and showing BULLISH Sentiment

0 · Reply

Dogstocks12 Oct. 1 at 7:49 PM

$ROIV Another 330k, calls at the ask

0 · Reply

Dogstocks12 Oct. 1 at 4:38 PM

$ROIV Big money options is in at and near ask

0 · Reply

biggestponzi Oct. 1 at 4:34 PM

$ROIV They have gone from 8 billion to 6 billion in 2 years

0 · Reply

TwoSunNick Oct. 1 at 4:33 PM

$ROIV Take Off 🚀

0 · Reply

biggestponzi Oct. 1 at 4:16 PM

$ROIV Hilarious they loose a billion a year

0 · Reply

SpaceCityKid Oct. 1 at 1:50 PM

$ROIV Breaking out of falling flag. Needs volume

0 · Reply

NakdEnergy Oct. 1 at 12:25 PM

$ABUS here’s a thought from left field, Vivek’s $ASST buys $ABUS maybe even $ROIV

3 · Reply

DocPharm Sep. 30 at 4:56 PM

$ABUS $NVO $ROIV $XBI 😘 gettin ready

2 · Reply

highnihilism Sep. 30 at 10:09 AM

$WRB WR Berkley: 47 trades, $44K vs $54K avg (0.81x). $39K calls / $5K puts. $ROIV Roivant Sciences: 143 trades, $48K vs $417K avg (0.12x !!!). $39K calls / $9K puts. $NPWR Net Power: 90 trades, $42K vs $124K avg (0.34x). $39K calls / $4K puts. $AM Antero Midstream: 323 trades, $54K vs $101K avg (0.54x). $38K calls / $16K puts.

0 · Reply

DocPharm Sep. 29 at 3:43 PM

$XBI cruisin near $100 Beyond and bios likely to go a lil ape shiii $ABUS $ROIV $NVO

0 · Reply

History101 Sep. 28 at 5:05 PM

$MRNA and $ROIV will be the recipient of that $2-$3B...

0 · Reply

SweepCastApp Sep. 26 at 6:57 PM

$ROIV: TRADE CALL orders came through 5028 @ 0.25, Strike 15.0, Exp 10/17/2025, Premium $125,700, Sentiment BEARISH

0 · Reply

DocPharm Sep. 26 at 4:30 PM

$ROIV gonna pop soon - will carry $ABUS Will they drop a licensing / partnership news piece in the near future 🤔 #HepB

0 · Reply

Alfalcon Sep. 26 at 1:42 PM

$ROIV

0 · Reply

renoH4 Sep. 25 at 6:11 PM

$ROIV ..breake away gap will not be closed - target 16 $ today or tomorrow

1 · Reply

Market Cap	11.04B
Revenue (ttm)	29.05M
Net Income (ttm)	-171.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-592.01%
Debt to Equity Ratio	0.00

Volume	5,295,300
Avg Vol	6,866,724
Day's Range	N/A - N/A
Shares Out	682.88M
Stochastic %K	99%
Beta	1.20
Analysts	Strong Sell
Price Target	$20.05